{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Parkinson%27s+Disease&page=21",
    "query": {
      "condition": "Parkinson's Disease",
      "page": 21
    },
    "page_size": 10
  },
  "pagination": {
    "page": 21,
    "page_size": 10,
    "total_count": 1409,
    "total_pages": 141,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Parkinson%27s+Disease&page=22&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Parkinson%27s+Disease&page=20&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T17:35:33.305Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04787965",
      "title": "Opicapone Treatment Initiation Open-Label Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "Opicapone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neurocrine Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 239,
      "start_date": "2021-03-01",
      "completion_date": "2022-08-04",
      "has_results": false,
      "last_update_posted_date": "2022-11-28",
      "last_synced_at": "2026-10-15T17:35:33.305Z",
      "location_count": 6,
      "location_summary": "Los Gatos, California • Memphis, Tennessee • Christiansburg, Virginia + 3 more",
      "locations": [
        {
          "city": "Los Gatos",
          "state": "California"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Christiansburg",
          "state": "Virginia"
        },
        {
          "city": "Norfolk",
          "state": "Virginia"
        },
        {
          "city": "Auburn",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04787965"
    },
    {
      "nct_id": "NCT02649608",
      "title": "An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "0.04 mg Lu AE04621",
          "type": "DRUG"
        },
        {
          "name": "0.08 mg Lu AE04621",
          "type": "DRUG"
        },
        {
          "name": "0.2 mg Lu AE04621",
          "type": "DRUG"
        },
        {
          "name": "0.4 mg Lu AE04621",
          "type": "DRUG"
        },
        {
          "name": "0.6 mg Lu AE04621",
          "type": "DRUG"
        },
        {
          "name": "0.8 mg Lu AE04621",
          "type": "DRUG"
        },
        {
          "name": "1.0 mg Lu AE04621",
          "type": "DRUG"
        },
        {
          "name": "1.2 mg Lu AE04621",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lundbeck A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "45 Years to 75 Years"
      },
      "enrollment_count": 15,
      "start_date": "2016-01",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2021-02-24",
      "last_synced_at": "2026-10-15T17:35:33.305Z",
      "location_count": 4,
      "location_summary": "Hallandale, Florida • Orlando, Florida • Chicago, Illinois + 1 more",
      "locations": [
        {
          "city": "Hallandale",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02649608"
    },
    {
      "nct_id": "NCT00165789",
      "title": "A Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor Fluctuations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "E2007",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2005-09",
      "completion_date": "2006-09",
      "has_results": true,
      "last_update_posted_date": "2015-06-02",
      "last_synced_at": "2026-10-15T17:35:33.305Z",
      "location_count": 10,
      "location_summary": "Little Rock, Arkansas • Oxnard, California • New Haven, Connecticut + 7 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Oxnard",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Delray Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00165789"
    },
    {
      "nct_id": "NCT03877510",
      "title": "Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease (PD) Participants With Motor Fluctuations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "IPX203",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Impax Laboratories, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 419,
      "start_date": "2019-04-03",
      "completion_date": "2022-03-21",
      "has_results": true,
      "last_update_posted_date": "2023-07-13",
      "last_synced_at": "2026-10-15T17:35:33.305Z",
      "location_count": 50,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03877510"
    },
    {
      "nct_id": "NCT00998660",
      "title": "RECHARGE Sub-Study to the Implantable Systems Performance Registry (ISPR)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Parkinson's Disease",
        "Essential Tremor",
        "Dystonia"
      ],
      "interventions": [
        {
          "name": "Activa RC",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "MedtronicNeuro",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "7 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2009-07",
      "completion_date": "2013-07",
      "has_results": true,
      "last_update_posted_date": "2015-03-06",
      "last_synced_at": "2026-10-15T17:35:33.305Z",
      "location_count": 5,
      "location_summary": "Washington D.C., District of Columbia • Cincinnati, Ohio • Nashville, Tennessee + 2 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Tyler",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00998660"
    },
    {
      "nct_id": "NCT05377281",
      "title": "Feasibility and Safety of autoloGous UncondItioneD pEripheral Nerve Tissue Delivery to the Substantia Nigra (GUIDE)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "Peripheral Nerve Tissue Implantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Craig van Horne, MD, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 10,
      "start_date": "2022-07-07",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-31",
      "last_synced_at": "2026-10-15T17:35:33.305Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05377281"
    },
    {
      "nct_id": "NCT04148391",
      "title": "NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mild Cognitive Impairment",
        "Mild Dementia",
        "Parkinson Disease",
        "Lewy Body Disease"
      ],
      "interventions": [
        {
          "name": "Placebo Oral Capsule",
          "type": "DRUG"
        },
        {
          "name": "NYX-458",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aptinyx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "50 Years to 80 Years"
      },
      "enrollment_count": 99,
      "start_date": "2019-11-14",
      "completion_date": "2022-12-30",
      "has_results": false,
      "last_update_posted_date": "2022-10-27",
      "last_synced_at": "2026-10-15T17:35:33.305Z",
      "location_count": 26,
      "location_summary": "Scottsdale, Arizona • Fresno, California • Simi Valley, California + 20 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Simi Valley",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04148391"
    },
    {
      "nct_id": "NCT04377945",
      "title": "Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dyskinesias",
        "Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "Part 1, JM-010 component Group A",
          "type": "DRUG"
        },
        {
          "name": "Part 1, JM-010 component Group B",
          "type": "DRUG"
        },
        {
          "name": "Part 1, JM-010 component Group C",
          "type": "DRUG"
        },
        {
          "name": "Part 1, Placebo Group",
          "type": "DRUG"
        },
        {
          "name": "Part 2, JM-010 combination Group A",
          "type": "DRUG"
        },
        {
          "name": "Part 2, JM-010 combination Group B",
          "type": "DRUG"
        },
        {
          "name": "Part 2, JM-010 component Group C",
          "type": "DRUG"
        },
        {
          "name": "Part 2, Placebo Group",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bukwang Pharmaceutical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 41,
      "start_date": "2021-04-28",
      "completion_date": "2024-02-14",
      "has_results": false,
      "last_update_posted_date": "2024-06-17",
      "last_synced_at": "2026-10-15T17:35:33.305Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • Detroit, Michigan",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04377945"
    },
    {
      "nct_id": "NCT01494532",
      "title": "A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "ropinirole/L-dopa",
          "type": "DRUG"
        },
        {
          "name": "placebo/L-dopa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 352,
      "start_date": "2012-04-02",
      "completion_date": "2014-11-18",
      "has_results": true,
      "last_update_posted_date": "2018-06-20",
      "last_synced_at": "2026-10-15T17:35:33.305Z",
      "location_count": 9,
      "location_summary": "Fountain Valley, California • Pasadena, California • Reseda, California + 6 more",
      "locations": [
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Reseda",
          "state": "California"
        },
        {
          "city": "Ventura",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01494532"
    },
    {
      "nct_id": "NCT03178786",
      "title": "Visual Spatial Exploration and Art Therapy Intervention in Patients Diagnosed With Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "PAT sessions",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 72,
      "start_date": "2017-07-18",
      "completion_date": "2020-08-10",
      "has_results": false,
      "last_update_posted_date": "2022-03-21",
      "last_synced_at": "2026-10-15T17:35:33.305Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03178786"
    }
  ]
}